Stent thrombosis redux - The FDA perspective

被引：209

作者：

Farb, Andrew ^{[1
]}

Boam, Ashley B. ^{[1
]}

机构：

[1] US FDA, Intervent Cardiol Devices Branch, Off Device Evaluat, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA

来源：

关键词：

D O I：

10.1056/NEJMp068304

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：984 / 987

页数：4

共 5 条

[1] American College of Cardiology, 2006, J Am Coll Cardiol, V48, pe1, DOI 10.1016/j.jacc.2006.05.021
[2] CAMENZIND E, 2006, WORLD C CARD 2006 BA
[3] Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation
Eisenstein, Eric L.
Anstrom, Kevin J.
Kong, David F.
Shaw, Linda K.
Tuttle, Robert H.
Mark, Daniel B.
Kramer, Judith M.
Harrington, Robert A.
Matchar, David B.
Kandzari, David E.
Peterson, Eric D.
Schulman, Kevin A.
Califf, Robert M.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (02): : 159 - 168
[4] Problems with drug-eluting coronary stents - The FDA perspective
Muni, NI
Gross, TP
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (16) : 1593 - 1595
[5] Wenaweser P., 2006, WORLD C CARD 2006 BA